|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
21
|
|
pubmed:dateCreated |
2007-11-2
|
|
pubmed:abstractText |
Human melanoma cells express shared antigens recognized by CD8(+) T lymphocytes, the most common of which are melanocytic differentiation proteins and cancer-testis antigens. However, peptide vaccines for melanoma usually target only one or two MHC class I-associated peptide antigens. Because melanomas commonly evade immune recognition by selective antigen loss, optimization of melanoma vaccines may require development of more complex multipeptide vaccines.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:Chianese-BullockKimberly AKA,
pubmed-author:FinkRobynR,
pubmed-author:GroshWilliam WWW,
pubmed-author:HibbittsSarahS,
pubmed-author:JohansenNaomiN,
pubmed-author:MurphyCherylC,
pubmed-author:NeesePatrice YPY,
pubmed-author:PattersonJames WJW,
pubmed-author:PetroniGina RGR,
pubmed-author:RehmPatrice KPK,
pubmed-author:SlingluffCraig LCLJr,
pubmed-author:SmolkinMark EME,
pubmed-author:YamshchikovGalina VGV
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
13
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
6386-95
|
|
pubmed:meshHeading |
pubmed-meshheading:17975151-Adjuvants, Immunologic,
pubmed-meshheading:17975151-Adult,
pubmed-meshheading:17975151-Aged,
pubmed-meshheading:17975151-CD8-Positive T-Lymphocytes,
pubmed-meshheading:17975151-Cancer Vaccines,
pubmed-meshheading:17975151-Epitopes,
pubmed-meshheading:17975151-Female,
pubmed-meshheading:17975151-HLA Antigens,
pubmed-meshheading:17975151-Histocompatibility Antigens Class I,
pubmed-meshheading:17975151-Humans,
pubmed-meshheading:17975151-Immune System,
pubmed-meshheading:17975151-Lymphocytes,
pubmed-meshheading:17975151-Male,
pubmed-meshheading:17975151-Medical Oncology,
pubmed-meshheading:17975151-Melanoma,
pubmed-meshheading:17975151-Middle Aged,
pubmed-meshheading:17975151-Peptides,
pubmed-meshheading:17975151-Treatment Outcome,
pubmed-meshheading:17975151-Vaccines, Subunit
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting.
|
|
pubmed:affiliation |
Department of Surgery, University of Virginia, Charlottesville, Virginia 22908, USA. cls8h@virginia.edu
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II,
Research Support, N.I.H., Extramural
|
